rationale of using different biological therapies in rheumatoid arthritis使用不同的生物治疗类风湿性关节炎的基本原理.pdfVIP

Geyer and Müller-Ladner Arthritis Research Therapy 2010, 12:214 /content/12/4/214 R E V I E W Rationale of using dif erent biological therapies in rheumatoid arthritis Matthias Geyer and Ulf Müller-Ladner* stage-adapted medication evaluated continu ously in Abstract close agreement with the patient [1,2]. Due to ongoing developments of novel agents in the Past pharmacologic options used to induce remission i eld of biological pharmacotherapy, there are now from RA included chrysotherapy, which became the fi rst more arrows available in clinicians’ quivers for the established ‘gold’ standard. In 1928, Jacques Forestier had treatment of rheumatic conditions. As a consequence, already started to use gold salts therapeutically in France, however, clear treatment strategies have to be assuming an infectious factor in RA, which was in the dei ned in order to guarantee a qualitatively high and tradition of Robert Koch’s evaluation of gold compounds individually stage-adapted, state-of-the-art regimen against pure cultures of Mycobacterium tuberculosis [3]. for af ected patients. This review summarizes recent Gold salts, however, were just one drug amongst a grow- evidence regarding the rationale of using dif erent ing number of long-acting, remission-inducing agents biological therapies to treat rheumatoid arthritis, showing only slow action in decreasing the infl ammatory the most common inl ammatory joint disorder after activity of RA. Owing to this mode of action, they have ac